Miguel‐Angel Perales

33.1k total citations · 6 hit papers
450 papers, 10.1k citations indexed

About

Miguel‐Angel Perales is a scholar working on Oncology, Hematology and Immunology. According to data from OpenAlex, Miguel‐Angel Perales has authored 450 papers receiving a total of 10.1k indexed citations (citations by other indexed papers that have themselves been cited), including 217 papers in Oncology, 188 papers in Hematology and 119 papers in Immunology. Recurrent topics in Miguel‐Angel Perales's work include Hematopoietic Stem Cell Transplantation (157 papers), CAR-T cell therapy research (143 papers) and Acute Myeloid Leukemia Research (69 papers). Miguel‐Angel Perales is often cited by papers focused on Hematopoietic Stem Cell Transplantation (157 papers), CAR-T cell therapy research (143 papers) and Acute Myeloid Leukemia Research (69 papers). Miguel‐Angel Perales collaborates with scholars based in United States, Spain and Canada. Miguel‐Angel Perales's co-authors include Marcel R.M. van den Brink, Sergio Giralt, Juliet N. Barker, Ann A. Jakubowski, Eric G. Pamer, Ying Taur, Jedd D. Wolchok, Robert R. Jenq, Alan N. Houghton and Parastoo B. Dahi and has published in prestigious journals such as Nature Medicine, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Miguel‐Angel Perales

403 papers receiving 10.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intestinal Domination and the Risk of Bacteremia in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

2012 676 citations Ying Taur, Yeon Joo Lee et al. Clinical Infectious Diseases profile →
The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation

2014 614 citations Ying Taur, Robert R. Jenq et al. Blood profile →
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

2021 202 citations Miguel‐Angel Perales, Bronwen E. Shaw et al. profile →
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

2024 132 citations Marcelo C. Pasquini, David L. Porter et al. profile →
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

2024 99 citations David M. Cordas dos Santos, Roni Shouval et al. profile →
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients

2024 44 citations Roni Shouval, Edward R. Scheffer Cliff et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Miguel‐Angel Perales United States	52	4.7k	3.0k	3.0k	2.0k	1.5k	450	10.1k
Takanori Teshima Japan	52	2.5k 0.5×	5.0k 1.6×	5.6k 1.8×	1.8k 0.9×	556 0.4×	486	10.6k
Jan J. Cornelissen Netherlands	58	3.4k 0.7×	2.9k 1.0×	7.1k 2.4×	1.9k 1.0×	1.5k 1.0×	319	13.0k
Olivier Lambotte France	56	3.5k 0.7×	5.9k 1.9×	2.2k 0.7×	1.5k 0.7×	3.8k 2.4×	240	13.9k
Andrew R. Gennery United Kingdom	51	1.5k 0.3×	3.9k 1.3×	2.3k 0.8×	2.7k 1.4×	894 0.6×	250	8.8k
W. Conrad Liles United States	52	2.6k 0.5×	2.9k 0.9×	1.3k 0.4×	2.0k 1.0×	1.2k 0.8×	158	9.9k
Amelia Langston United States	41	2.1k 0.4×	884 0.3×	2.3k 0.8×	1.0k 0.5×	2.4k 1.5×	177	7.5k
Simone Cesaro Italy	47	2.6k 0.6×	1.3k 0.4×	2.9k 1.0×	561 0.3×	2.4k 1.6×	289	8.3k
Jan Storek Canada	45	2.0k 0.4×	3.0k 1.0×	4.1k 1.4×	420 0.2×	875 0.6×	187	7.6k
Adriana Zeevi United States	63	2.3k 0.5×	3.8k 1.3×	1.2k 0.4×	1.2k 0.6×	729 0.5×	431	16.4k
Anna Sureda Spain	56	5.6k 1.2×	2.2k 0.7×	5.0k 1.7×	1.5k 0.8×	453 0.3×	465	11.7k

Countries citing papers authored by Miguel‐Angel Perales

Since Specialization

Citations

This map shows the geographic impact of Miguel‐Angel Perales's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miguel‐Angel Perales with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miguel‐Angel Perales more than expected).

Fields of papers citing papers by Miguel‐Angel Perales

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miguel‐Angel Perales. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miguel‐Angel Perales. The network helps show where Miguel‐Angel Perales may publish in the future.

Co-authorship network of co-authors of Miguel‐Angel Perales

This figure shows the co-authorship network connecting the top 25 collaborators of Miguel‐Angel Perales. A scholar is included among the top collaborators of Miguel‐Angel Perales based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miguel‐Angel Perales. Miguel‐Angel Perales is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shah, Gunjan L., Tomalika R. Ullah, MM Hafeez, et al.. (2025). Infusional N-Acetylcysteine Enhances CAR T Cell Persistence in Patients with Aggressive B-Cell Lymphomas. Transplantation and Cellular Therapy. 31(2). S238–S239.

Hunter, Bradley D., Matthew A. Lunning, Sairah Ahmed, et al.. (2025). CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting. Transplantation and Cellular Therapy. 32(2). 171.e1–171.e12. 1 indexed citations

Ghobadi, Armin, Javier Muñoz, Jason R. Westin, et al.. (2024). Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood Advances. 8(11). 2982–2990. 4 indexed citations

Stern, Anat, Yeon Joo Lee, Y. Li, et al.. (2024). Letermovir for Prevention of Recurrent Cytomegalovirus in High-Risk Allogeneic Hematopoietic Cell Transplantation Recipients. Transplantation and Cellular Therapy. 31(2). 105.e1–105.e9.

Cho, Christina, Emily S. Patterson, Elizabeth Giles, et al.. (2024). Health-Related Values Discussions with Patients Undergoing Allogeneic and Autologous Stem Cell Transplant: Feasibility and Acceptability of an Early Primary Palliative Care Intervention. Transplantation and Cellular Therapy. 31(2). 107.e1–107.e12.

Shouval, Roni, et al.. (2024). Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients. Clinical Cancer Research. 30(20). 4690–4700. 44 indexed citations breakdown →

Riedell, Peter A., Loretta J. Nastoupil, Alejandro Luna, et al.. (2024). Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Advances. 9(5). 1232–1241. 6 indexed citations

Fein, Joshua, Sean M. Devlin, Gonca Ozcan, et al.. (2024). A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation. Leukemia & lymphoma. 66(4). 713–720.

Perales, Miguel‐Angel & Sairah Ahmed. (2024). When to use stem cell transplantation for classical Hodgkin lymphoma. Hematology. 2024(1). 517–523. 1 indexed citations

10.

Nikiforow, Sarah, Michael K. Mansour, Zhen‐Huan Hu, et al.. (2024). Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?. UNC Libraries.

11.

Anderson, Larry D., Binod Dhakal, Tania Jain, et al.. (2023). Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy. 30(1). 17–37. 24 indexed citations

12.

Koehne, Guenther, Benjamin Tomlinson, Hyung C. Suh, et al.. (2023). P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS. HemaSphere. 7(S3). e24418bc–e24418bc. 3 indexed citations

13.

Williamson, Staci, Jamie Brower, Veronika Bachanová, et al.. (2023). Prolonged Cytopenias after Commercial CAR T-Cell Therapy with Tisagenlecleucel and Axicabtagene Ciloleucel for Relapsed and Refractory DLBCL. Transplantation and Cellular Therapy. 29(2). S220–S221. 1 indexed citations

14.

Ghobadi, Armin, Javier Muñoz, Jason R. Westin, et al.. (2023). Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) Zuma-7 Study. Transplantation and Cellular Therapy. 29(2). S371–S372. 1 indexed citations

15.

Zhang, Allen W., Sejal Morjaria, Anna Kaltsas, et al.. (2021). The Effect of Neutropenia and Filgrastim (G-CSF) on Cancer Patients With Coronavirus Disease 2019 (COVID-19) Infection. Clinical Infectious Diseases. 74(4). 567–574. 24 indexed citations

16.

Dehn, Jason, Stephen R. Spellman, Carolyn Katovich Hurley, et al.. (2019). Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 134(12). 924–934. 173 indexed citations

17.

Lee, Yeon Joo, Robert R. Jenq, Eric R. Littmann, et al.. (2017). Protective Factors in the Intestinal Microbiome Against Clostridium difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. The Journal of Infectious Diseases. 215(7). 1117–1123. 65 indexed citations

18.

Burns, Linda J., James Gajewski, Navneet S. Majhail, et al.. (2014). Challenges and Potential Solutions for Recruitment and Retention of Hematopoietic Cell Transplantation Physicians: The National Marrow Donor Program’s System Capacity Initiative Physician Workforce Group Report. Biology of Blood and Marrow Transplantation. 20(5). 617–621. 12 indexed citations

19.

Barker, Juliet N., Ekaterina Doubrovina, Craig S. Sauter, et al.. (2010). Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood. 116(23). 5045–5049. 163 indexed citations

20.

Cohen, Adam D., David Schaer, Cailian Liu, et al.. (2010). Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation. PLoS ONE. 5(5). e10436–e10436. 199 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact